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The ESC guidelines help physicians to make decisions in their
practice, but do not override the responsibility of health
professionals to make decisions and to follow the rules and
regulations applicable to drugs and devices.2. Introduction
In 2000, the First Global MI Task Force presented a new definition
of MI, which implied that any necrosis in the setting of
myocardial ischaemia should be labelled as MI. These principles
were further refined by the Second Global MI Task Force, leading
to the Universal Definition of Myocardial Infarction Consensus
Document in 2007, which emphasized the different conditions
which might lead to an MI. However, the development of even
more sensitive assays for markers of myocardial necrosis man-
dates further revision, particularly when such necrosis occurs in
the setting of the critically ill, after percutaneous coronary
procedures or after cardiac surgery. The Third Global MI Task
Force has continued the Joint ESC/ACCF/AHA/WHF efforts by
integrating these insights and new data into the current docu-
ment, which now recognizes that very small amounts of
myocardial injury or necrosis can be detected by biochemical
markers and/or imaging.
2.1. What is new in the third universal definition
of myocardial infarction Criteria for an acute myocardial infarction: new identifica-
tion of intracoronary thrombus by angiography or autopsy. Elevation of cardiac troponin values because of myocardial
injury:
J myocardial injury related to primary myocardial
ischaemia (MI type I);
J myocardial injury related to supply/demand imbalance
(MI type II);
J myocardial injury not related to myocardial ischaemia.New multifactorial or undetermined myocardial injury
(heart failure, stress Tako-tsubo cardiomyopathy,
severe pulmonary embolism or hypertension, sepsis and
critically ill patients, renal failure, severe acute neurologi-
cal diseases e.g. stroke, subarachnoid haemorrhage,
infiltrative disease, e.g. amyloidosis, sarcoidosis, strenuous
exercise). ECG criteria of ST elevation age and gender specific.
 Criteria for periprocedural MI.
2.1.1. Definition of myocardial infarction
Definition of myocardial infarction is given in Table 1.
2.1.2. Pathological characteristics of myocardial ischaemia
and infarction
MI is defined in pathology as myocardial cell death due to
prolonged myocardial ischaemia. After the onset of myocardial
ischaemia, histological cell death is not immediate, but takes
a finite period of time to develop—as little as 20 min—or less
in some animal models. It takes several hours before myo-
cardial necrosis can be identified by macroscopic or micro-
scopic post-mortem examination. Complete necrosis of
myocardial cells at risk requires at least 2–4 h, or longer,
depending on the presence of collateral circulation to the
ischaemic zone, persistent or intermittent coronary arterial
occlusion, the sensitivity of the myocytes to ischaemia,
preconditioning, and individual demand for oxygen and
nutrients. The entire process leading to a healed infarction
usually takes at least 5–6 weeks. Reperfusion may alter the
macroscopic and microscopic appearance.
2.1.3. Biomarker detection of myocardial injury with necrosis
Myocardial injury is detected when blood levels of sensitive and
specific biomarkers such as cTn or the MB fraction of creatine
kinase (CKMB) are increased. Cardiac troponin I and T are
components of the contractile apparatus of myocardial cells
and are expressed almost exclusively in the heart. Although
elevations of these biomarkers in the blood reflect injury leading
to necrosis of myocardial cells, they do not indicate the
Table 1 – Definition of myocardial infarction.
Criteria for acute myocardial infarction
The term acute myocardial infarction (MI) should be used when there is evidence of myocardial necrosis in a clinical setting consistent with
acute myocardial ischaemia.
Under these conditions any one of the following criteria meets the diagnosis for MI:
Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least one value above the 99th percentile
upper reference limit (URL) and with at least one of the following:
 Symptoms of ischaemia.
 New or presumed new significant ST-segment–Twave (ST–T) changes or new left bundle branch block (LBBB).
 Development of pathological Q waves in the ECG.
 Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
 Identification of an intracoronary thrombus by angiography or autopsy.
Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes or new LBBB, but death
occurred before cardiac biomarkers were obtained, or before cardiac biomarker values would be increased.
Percutaneous coronary intervention (PCI) related MI is arbitrarily defined by elevation of cTn values (45 99th percentile URL) in patients
with normal baseline values (r99th percentile URL) or a rise of cTn values420% if the baseline values are elevated and are stable or falling. In
addition, either (i) symptoms suggestive of myocardial ischaemia or (ii) new ischaemic ECG changes or (iii) angiographic findings consistent
with a procedural complication or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality are
required.
Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of myocardial ischaemia and with a
rise and/or fall of cardiac biomarker values with at least one value above the 99th percentile URL.
Coronary artery bypass grafting (CABG) related MI is arbitrarily defined by elevation of cardiac biomarker values (410 99th percentile URL)
in patients with normal baseline cTn values (r99th percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii)
angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or
new regional wall motion abnormality.
Criteria for prior myocardial infarction
Any one of the following criteria meets the diagnosis for prior MI:
Pathological Q waves with or without symptoms in the absence of non-ischaemic causes.
Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischaemic cause.
Pathological findings of a prior MI.
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gested for release of structural proteins from the myocardium,
including normal turnover of myocardial cells, apoptosis, cellular
release of troponin degradation products, increased cellular wall
permeability, formation and release of membranous blebs, and
myocyte necrosis. Myocardial necrosis due to myocardial ischae-
mia is designated as MI. Myocardial injury with necrosis may be
detected with heart failure (HF), renal failure, myocarditis,
arrhythmias, pulmonary embolism or otherwise uneventful
percutaneous or surgical coronary procedures. These should
not be labelled as MI or a complication of the procedures, but
rather as myocardial injury. It is important to distinguish a rise
and/or fall of cTn values, from chronic elevations that tend not
to change acutely. The multifactorial contributions resulting in
the myocardial injury should be described in the patient record.
The preferred biomarker is cTn (I or T), which has high
myocardial tissue specificity as well as high clinical sensitivity.
Detection of a rise and/or fall of themeasurements is essential to
the diagnosis of acute MI. An increased cTn concentration is
defined as a value exceeding the 99th percentile of a normal
reference population [upper reference limit (URL)]. This discri-
minatory 99th percentile is designated as the decision level for
the diagnosis of MI and must be determined for each specific
assay with appropriate quality control in each laboratory. Values
should be presented as nanograms per litre (ng/l) or picograms
per millilitre (pg/ml) to make whole numbers. Optimal precision
of cTn estimation is described by coefficient of variation (CV) atthe URL for each assayr10%. Better precision (CVr10%) allows
for more sensitive assays and facilitates the detection of chan-
ging values. The use of assays that do not have CVo10% does
not cause false positive results. Assays with CV 4 20 % should
not be used. It is acknowledged that pre-analytic and analytic
problems can induce elevated and reduced values of cTn. Blood
samples for the measurement of cTn should be drawn on first
assessment and repeated 3–6 h later. Later samples are required
if further ischaemic episodes occur, or when the timing of the
initial symptoms is unclear. To establish the diagnosis of MI, a
rise and/or fall in values with at least one value above the
decision level (URL) is required. A rising or falling pattern is not
absolutely necessary to make the diagnosis of MI if a patient
with a high pre-test risk of MI presents late after symptom onset;
for example, on the slow-declining portion of that curve. Values
may remain elevated for 2 weeks or more following the onset of
myocyte necrosis. Sex-dependent values may be recommended
for high-sensitivity troponin assays. An elevated cTn value with
or without a dynamic pattern of values or in the absence of
clinical evidence of ischaemia, should prompt a search for other
diagnoses associated with myocardial injury, such as myocardi-
tis, aortic dissection, pulmonary embolism, or HF. If a cTn assay
is not available, the best alternative is CKMB (measured by mass
assay). As with troponin, an increased CKMB value is defined as
a measurement above URL (99th percentile), which is designated
as the decision level for the diagnosis of MI. Sex-specific values
should be employed.
Table 2 – Elevation of cardiac troponin values because of
myocardial injury.
Injury related to primary myocardial ischaemia
Plaque rupture
Intraluminal coronary artery thrombus formation
Injury related to supply/demand imbalance of myocardial
ischaemia
Tachy-/brady-arrhythmias
Aortic dissection or severe aortic valve disease
Hypertrophic cardiomyopathy
Cardiogenic, hypovolaemic, or septic shock
Severe respiratory failure
Severe anaemia
Hypertension with or without LVH
Coronary spasm
Coronary embolism or vasculitis
Coronary endothelial dysfunction without significant CAD
Injury not related to myocardial ischaemia
Cardiac contusion, surgery, ablation, pacing, or defibrillator
shocks
Rhabdomyolysis with cardiac involvement
Myocarditis
Cardiotoxic agents, e.g. anthracyclines, herceptin
Multifactorial or indeterminate myocardial injury
Heart failure
Stress (Tako-tsubo) cardiomyopathy
Severe pulmonary embolism or pulmonary hypertension
Sepsis and critically ill patients
Renal failure
Severe acute neurological diseases, e.g. stroke, subarachnoid
haemorrhage
Infiltrative diseases, e.g. amyloidosis, sarcoidosis
Strenuous exercise
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cardiac troponin values because of myocardial injury are
shown in Table 2.2.1.4. Clinical features of myocardial ischaemia and
infarction
Onset of myocardial ischaemia is the initial step in the develop-
ment of MI and results from an imbalance between oxygen
supply and demand. Myocardial ischaemia in a clinical setting
can usually be identified from the patient’s history and from the
ECG. Possible ischaemic symptoms include various combinations
of chest, upper extremity, mandibular or epigastric discomfort
(with exertion or at rest) or an ischaemic equivalent such as
dyspnoea or fatigue. The discomfort associated with acute MI
usually lasts 420min. Often, the discomfort is diffuse—not
localized, nor positional, nor affected by movement of the
region—and it may be accompanied by diaphoresis, nausea or
syncope. However, these symptoms are not specific for myocar-
dial ischaemia. Accordingly, they may be misdiagnosed and
attributed to gastrointestinal, neurological, pulmonary or mus-
culoskeletal disorders. MI may occur with atypical symptoms—
such as palpitations or cardiac arrest—or even without symp-
toms; for example in women, the elderly, diabetics, or post-
operative and critically ill patients.3. Clinical classification of myocardial
infarction
For the sake of immediate treatment strategies, such as reperfu-
sion therapy, it is usual practice to designate MI in patients with
chest discomfort, or other ischaemic symptoms that develop ST
elevation in two contiguous leads (see ECG section), as an ‘ST
elevation MI’ (STEMI). In contrast, patients without ST elevation
at presentation are usually designated as having a ‘non-ST
elevation MI’ (NSTEMI). Many patients with MI develop Q waves
(Q wave MI), but others do not (non-Q MI). Patients without
elevated biomarker values can be diagnosed as having unstable
angina. In addition to these categories, MI is classified into
various types, based on pathological, clinical and prognostic
differences, along with different treatment strategies.
3.1. Spontaneous myocardial infarction (MI type 1)
This is an event related to atherosclerotic plaque rupture,
ulceration, fissuring, erosion, or dissection with resulting intra-
luminal thrombus in one or more of the coronary arteries,
leading to decreased myocardial blood flow or distal platelet
emboli with ensuing myocyte necrosis. The patient may have
underlying severe CAD but, on occasion, non-obstructive or
no CAD.
3.2. Myocardial infarction secondary to an ischaemic
imbalance (MI type 2)
In instances of myocardial injury with necrosis, where a condi-
tion other than CAD contributes to an imbalance between
myocardial oxygen supply and/or demand, the term ‘MI type 2’
is employed. In critically ill patients, or in patients undergoing
major (non-cardiac) surgery, elevated values of cardiac biomar-
kers may appear, due to the direct toxic effects of high circulat-
ing catecholamine levels. Also coronary vasospasm and/or
endothelial dysfunction have the potential to cause MI.
3.3. Cardiac death due to myocardial infarction (MI type 3)
Patients who suffer cardiac death, with symptoms suggestive
of myocardial ischaemia accompanied by presumed new
ischaemic ECG changes or new LBBB—but without available
biomarker values—may die before blood samples for biomar-
kers can be obtained, or before elevated cardiac biomarkers
can be identified. If patients present with clinical features of
myocardial ischaemia, or with presumed new ischaemic ECG
changes, they should be classified as having had a fatal MI,
even if cardiac biomarker evidence of MI is lacking.
3.4. Myocardial infarction associated with
revascularization procedures (MI types 4 and 5)
Periprocedural myocardial injury or infarction with elevated
cTn values may occur during mechanical revascularization
procedures, either by PCI or by coronary artery bypass
grafting (CABG). It is likely that limitation of such injury is
beneficial to the patient: however, a threshold for a worsen-
ing prognosis is not well defined. Subcategories of PCI-related
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may happen after the primary procedure.
3.5. Diagnostic criteria for myocardial infarction with PCI
(MI type 4)
Balloon inflation during PCI often causes transient ischaemia,
whether or not it is accompanied by chest pain or ST–T
changes. Myocardial injury with necrosis may result from
recognizable periprocedural events—alone or in combination—
such as coronary dissection, occlusion of a major coronary
artery or a side-branch, disruption of collateral flow, slow flow
or no-reflow, distal embolization, and microvascular plugging.
The occurrence of procedure-related myocardial cell
injury with necrosis can be detected by measurement of
cardiac biomarkers before the procedure, repeated 3–6 h later
and, optionally, further re-measurement 12 h thereafter.
Increasing levels can only be interpreted as procedure-
related myocardial injury if the pre-procedural cTn value is
normal (r99th percentile URL) or if levels are stable or falling.
In patients undergoing PCI with normal (o99th percentile
URL) baseline cTn concentrations, elevations of cTn4599th
percentile URL occurring within 48 h of the procedure—plus
either (i) evidence of prolonged ischaemia (Z20 min) as
demonstrated by prolonged chest pain, or (ii) ischaemic ST
changes or new pathological Q waves, or (iii) angiographic
evidence of a flow limiting complication, such as of loss of
patency of a side branch, persistent slow-flow or no-reflow,
embolization, or (iv) imaging evidence of new loss of viable
myocardium or new regional wall motion abnormality—is
defined as PCI-related MI (type 4a). This threshold of cTn
values4599th percentile URL is arbitrarily chosen. When a
cTn value is r599th percentile URL after PCI and the cTn
value was normal before the PCI—or when the cTn value is
4599th percentile URL in the absence of ischaemic, angio-
graphic or imaging findings—the term ‘myocardial injury’
should be used.
If the baseline cTn values are elevated and are stable or
falling, then a rise of 420% is required for the diagnosis of a
type 4a MI, as with reinfarction.
A subcategory of PCI-related MI is stent thrombosis, as
documented by angiography and/or at autopsy and a rise
and/or fall of cTn values 499th percentile URL (identified as
MI type 4b).
3.6. Diagnostic criteria for myocardial infarction with
CABG (MI type 5)
During CABG, numerous factors can lead to periprocedural
myocardial injury with necrosis. These include direct myo-
cardial trauma from (i) suture placement or manipulation of
the heart, (ii) coronary dissection, (iii) global or regional
ischaemia related to inadequate intra-operative cardiac pro-
tection, (iv) microvascular events related to reperfusion, (v)
myocardial injury induced by oxygen free radical generation,
or (vi) failure to reperfuse areas of the myocardium that are
not subtended by graftable vessels.
In patients with normal values before surgery, any
increase of cardiac biomarker values after CABG indicates
myocardial necrosis, implying that an increasing magnitudeof biomarker concentrations is likely to be related to an
impaired outcome.
In view of the adverse impact on survival observed in
patients with significant elevation of biomarker concentra-
tions, by arbitrary convention, cTn values41099th percen-
tile URL during the first 48 h following CABG, occurring from a
normal baseline cTn value (r99th percentile URL), and either
(i) new pathological Q waves or new LBBB, or (ii) angiogra-
phically documented new graft or new native coronary artery
occlusion, or (iii) imaging evidence of new loss of viable
myocardium or new regional wall motion abnormality,
should be considered as diagnostic of a CABG-related MI
(type 5). Cardiac biomarker release is considerably higher
after valve replacement with CABG than with bypass surgery
alone, and with on-pump CABG compared to off-pump CABG.3.7. Assessment of MI in patients undergoing other
cardiac procedures
New ST–T abnormalities are common in patients who
undergo cardiac surgery. When new pathological Q waves
appear in different territories than those identified before
surgery, MI (types 1 or 2) should be considered, particularly if
associated with elevated cardiac biomarker values, new wall
motion abnormalities or haemodynamic instability.
Novel procedures such as transcatheter aortic valve
implantation (TAVI) or mitral clip may cause myocardial
injury with necrosis, both by direct trauma to the myocar-
dium and by creating regional ischaemia from coronary
obstruction or embolization. It is likely that, similarly to
CABG, the more marked the elevation of the biomarker
values, the worse the prognosis—but data on that are not
available.
Ablation of arrhythmias involves controlled myocardial injury
with necrosis, by application of warming or cooling of the tissue.
An elevation of cTn values in this context should not be
labelled as MI.3.8. Myocardial infarction associated with non-cardiac
procedures
Perioperative MI is the most common major perioperative
vascular complication in major non-cardiac surgery, and is
associated with a poor prognosis. Most patients who have a
perioperative MI will not experience ischaemic symptoms.
Nevertheless, asymptomatic perioperative MI is as strongly
associated with 30-d mortality, as is symptomatic MI. Routine
monitoring of cardiac biomarkers in high-risk patients, both
prior to and 48–72 h after major surgery, is therefore recom-
mended. Many of the infarctions diagnosed in this context
are caused by a prolonged imbalance between myocardial
oxygen supply and demand, against a background of CAD.
Together with a rise and/or fall of cTn values, this indicates
MI type 2. However, substantial proportion of perioperative
MI patients may have plaque rupture leading to thrombus
formation, that is to say, MI type 1. Given the differences that
probably exist in the therapeutic approaches to each, close
clinical scrutiny and judgement is needed.
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Elevations of cTn values are common in patients in the
intensive care unit and are associated with adverse prog-
nosis, regardless of the underlying disease state. Some
elevations may reflect MI type 2 due to underlying CAD and
increased myocardial oxygen demand. Other patients may
have elevated values of cardiac biomarkers, due to myocar-
dial injury with necrosis induced by catecholamine or direct
toxic effect from circulating toxins. Moreover, in some
patients, MI type 1 may occur. If and when the patient
recovers from the critical illness, clinical judgement should
be employed to decide whether—and to what extent—further
evaluation for CAD or structural heart disease is indicated.
3.10. Myocardial injury or infarction associated with
heart failure
Detectable-to-clearly elevated cTn values, indicative of myo-
cardial injury with necrosis, may be seen in patients with HF
syndrome. Using high-sensitivity cTn assays, measurable cTn
concentrations may be present in nearly all patients with HF,
with a significant percentage exceeding the 99th percentile
URL, particularly in those with more severe HF syndrome,
such as in acutely decompensated HF.
Whilst MI type 1 is an important cause of acutely decom-
pensated HF—and should always be considered in the context of
an acute presentation—elevated cTn values alone do not estab-
lish the diagnosis of MI type 1 and may be seen in those with
non-ischaemic HF. MI type 2 may result from increased trans-
mural pressure, small-vessel coronary obstruction, endothelial
dysfunction, anaemia or hypotension. Direct cellular toxicity
related to inflammation, circulating neurohormones, infiltrative
processes, as well as myocarditis and stress cardiomyopathy,
may present with HF and abnormal cTn measurement.
The presence, magnitude and persistence of cTn elevation
in HF is increasingly accepted to be an independent predictor
of adverse outcomes in both acute and chronic HF syndrome,
irrespective of mechanism.
In the context of an acutely decompensated HF presentation,
cTn I or T should always be promptly measured and ECG
recorded, with the goal of identifying or excluding MI type 1 as
the precipitant. In this setting, elevated cTn values should be
interpreted with a high level of suspicion for MI type 1 if a
significant rise and/or fall of the marker are seen, or if it is
accompanied by ischaemic symptoms, new ischaemic ECG
changes or loss of myocardial function on non-invasive testing.
Coronary artery anatomymay often bewell-known; such knowl-
edge may be used to interpret abnormal troponin results. If
normal coronary arteries are present, either a type 2 MI or a non-
coronary mechanism for troponin release may be invoked.
When coronary anatomy is not established, the recognition of
a cTn value in excess of the 99th percentile URL alone is not
sufficient to make a diagnosis of acute MI due to CAD, nor is it
able to identify the mechanism for the abnormal cTn value.
In this setting, further information, such asmyocardial perfusion
studies, coronary angiography, or MRI is often required to better
understand the cause of the abnormal cTn measurement.
However, it may be difficult to establish the reason for cTn
abnormalities, even after such investigations.4. Electrocardiographic detection of
myocardial infarction
The ECG is an integral part of the diagnostic work-up of
patients with suspected MI and should be acquired and
interpreted promptly (i.e. target within 10 min) after clinical
presentation.
Dynamic changes in the ECG waveforms during acute
myocardial ischaemic episodes often require acquisition of
multiple ECGs, particularly if the ECG at initial presentation is
non-diagnostic. Serial recordings in symptomatic patients
with an initial non-diagnostic ECG should be performed at
15–30 min intervals or, if available, continuous computer-
assisted 12-lead ECG recording. Recurrence of symptoms
after an asymptomatic interval are an indication for a repeat
tracing and, in patients with evolving ECG abnormalities, a
pre-discharge ECG should be acquired as a baseline for future
comparison. Acute or evolving changes in the ST–T wave-
forms and Q waves, when present, potentially allow the
clinician to time the event and to determine therapeutic
strategy.
The ECG by itself is often insufficient to diagnose acute
myocardial ischaemia or infarction, since ST deviation may be
observed in other conditions, such as acute pericarditis,
left ventricular hypertrophy (LVH), left bundle branch block
(LBBB), Brugada syndrome, stress cardiomyopathy, and early
repolarization patterns. Prolonged new ST-segment elevation
(e.g. 420min), particularly when associated with reciprocal
ST-segment depression, usually reflects acute coronary occlusion
and results in myocardial injury with necrosis. As in cardiomyo-
pathy, Q waves may also occur due to myocardial fibrosis in the
absence of CAD. ECG abnormalities of myocardial ischaemia or
infarctionmay be inscribed in the PR segment, the QRS complex,
the ST-segment or the T wave. The earliest manifestations of
myocardial ischaemia are typically T wave and ST-segment
changes. Increased hyperacute T wave amplitude, with promi-
nent symmetrical Twaves in at least two contiguous leads, is an
early sign that may precede the elevation of the ST-segment.
Transient Q waves may be observed during an episode of
acute ischaemia or (rarely) during acute MI with successful
reperfusion.
The J point is used to determine the magnitude of the
ST-segment shift. New, or presumed new, J point elevation
Z0.1mV is required in all leads other than V2 and V3. In healthy
men under age 40, J-point elevation can be as much as 0.25mV
in leads V2 or V3, but it decreases with increasing age. Sex
differences require different cut-points for women, since J point
elevation in healthy women in leads V2 and V3 is less than in
men. Supplemental leads such as V3R and V4R reflect the free
wall of the right ventricle and V7–V9 the infero-basal wall.
Electrocardiographic evidence of myocardial ischaemia in the
distribution of a left circumflex artery is often overlooked and is
best captured using posterior leads at the fifth intercostal space
(V7 at the left posterior axillary line, V8 at the left mid-scapular
line, and V9 at the left paraspinal border).
ST depression in leads V1–V3 may be suggestive of infero-
basal myocardial ischaemia (posterior infarction), especially
when the terminal T wave is positive (ST elevation equivalent),
however this is non-specific. In patients with inferior and
Table 3 – ST segment elevation criteria: (age and gender
specific).
New ST segment elevation at J point in 2 contiguous leads with the
following cut-off points:
 40.1 mV in all leads except leads V2, V3 in men and women
 In leads V2, V340.2 mV in men440 years
 In leads V2, V340.25 mV in meno40 years
 In leads V2, V340.15 mV in women
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and V4R should be recorded, since ST elevation Z0.05mV
(Z0.1mV in men, 30 years old) provides supportive criteria for
the diagnosis. During an episode of acute chest discomfort,
pseudonormalization of previously inverted T waves may indi-
cate acute myocardial ischaemia. Pulmonary embolism, intra-
cranial processes, electrolyte abnormalities, hypothermia, or
peri-/myocarditis may also result in ST–T abnormalities and
should be considered in the differential diagnosis. The diagnosis
of MI is more difficult in the presence of LBBB. However,
concordant ST-segment elevation or a previous ECG may be
helpful to determine the presence of acute MI in this setting. In
patients with right bundle branch block (RBBB), ST–T abnormal-
ities in leads V1–V3 are common, making it difficult to assess the
presence of ischemia in these leads: however, when new ST
elevation or Q waves are found, myocardial ischemia or infarc-
tion should be considered.
Age and gender specific ST segment elevation criteria are
given in Table 3.4.1. Prior myocardial infarction
Q waves or QS complexes in the absence of QRS confounders
are pathognomonic of a prior MI in patients with ischaemic
heart disease, regardless of symptoms. The specificity of the
ECG diagnosis for MI is greatest when Q waves occur in
several leads or lead groupings. When the Q waves are
associated with ST deviations or Twave changes in the same
leads, the likelihood of MI is increased.4.2. ECG changes associated with prior myocardial infarction
Any Q wave in leads V2–V3 Z0.02 s or QS complex in leads V2
and V3.
Q waveZ0.03 s andZ0.1 mV deep or QS complex in leads
I, II, aVL, aVF or V1–V6 in any two leads of a contiguous lead
grouping (I, aVL; V1–V6; II, III, aVF). R wave Z0.04 s in V1–V2
and R/S Z1 with a concordant positive Twave in absence of
conduction defect.4.3. Conditions that confound the ECG diagnosis of
myocardial infarction
AQS complex in lead V1 is normal. A Q wave 0.03 s and 25% of
the R wave amplitude in lead III is normal if the frontal QRS
axis is between 301 and 01. A Q wave may also be normal in
aVL if the frontal QRS axis is between 601 and 901. Septal Qwaves are small, non-pathological Q waves 0.03 s and 25% of
the R-wave amplitude in leads I, aVL, aVF, and V4–V6.
Pre-excitation, obstructive, dilated or stress cardiomyopa-
thy, cardiac amyloidosis, LBBB, left anterior hemiblock, LVH,
right ventricular hypertrophy, myocarditis, acute cor pulmo-
nale, or hyperkalaemia may be associated with Q waves or QS
complexes in the absence of MI.5. Imaging techniques
The underlying rationale is that regional myocardial hypo-
perfusion and ischaemia lead to changes of imaging para-
meters: perfusion, myocyte viability, myocardial thickness,
thickening, motion and kinetics of paramagnetic or radio-
opaque contrast agents. Used imaging techniques in acute
and chronic infarction are therefore echocardiography, radio-
nuclide ventriculography, myocardial perfusion scintigraphy
(MPS) using single photon emission computed tomography
(SPECT), and magnetic resonance imaging (MRI). Positron
emission tomography (PET) and X-ray computed tomography
(CT) are less common. There is considerable overlap in their
capabilities and each of the techniques can, to a greater or
lesser extent, assess myocardial viability, perfusion and
function. Only the radionuclide techniques provide a direct
assessment of myocyte viability, because of the inherent
properties of the tracers used. Other techniques provide
indirect assessments of myocardial viability, such as contrac-
tile response to dobutamine by echocardiography or myocar-
dial fibrosis by MR.
5.1. Echocardiography
The strength of echocardiography is the assessment of cardiac
structure and function, in particular myocardial thickness,
thickening and motion. Echocardiographic contrast agents can
improve visualisation of the endocardial border and can be used
to assess myocardial perfusion and microvascular obstruction.
Tissue Doppler and strain imaging permit quantification of
global and regional function.
5.2. Radionuclide imaging
Radionuclide tracers thallium-201, technetium-99m MIBI and
tetrofosmin and PET tracers F-2-fluorodeoxyglucose (FDG)
and rubidium-82 allow viable myocytes to be imaged directly.
The strength of the SPECT techniques is that these are the
only commonly available direct methods of assessing viabi-
lity, although the relatively low resolution of the images
leaves them at a disadvantage for detecting small areas of
MI. The techniques also detect areas of MI and inducible
perfusion abnormalities. ECG-gated imaging provides a
reliable assessment of myocardial motion, thickening and
global function.
5.3. Magnetic resonance imaging
MRI provide an accurate assessment of myocardial function.
Paramagnetic contrast agents can be used to assess myocardial
perfusion and the increase in extracellular space that is
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been used in the setting of acute MI. Imaging of myocardial
fibrosis by delayed contrast enhancement is able to detect even
small areas of subendocardial MI. It is also of value in
differential diagnosis of myocarditis.
5.4. Computed tomography
Infarcted myocardium is initially visible as a focal area of
decreased left ventricle (LV) enhancement, but later imaging
shows hyperenhancement and contrast-enhanced CT may be
performed for suspected pulmonary embolism and aortic
dissection—conditions with clinical features that overlap
with those of acute MI—but the technique is not used
routinely. Similarly, CT assessment of myocardial perfusion
is technically feasible but not yet fully validated.
5.5. Applying imaging in acute myocardial infarction
Detection of new wall motion abnormalities or loss of viable
myocardium in the absence of non-ischaemic cause meets the
criteria for MI. Normal function and viability have a very high
negative predictive value but the positive predictive value is not
high because abnormal regional myocardial motion and thick-
ening may be caused by prior MI, stunning, hibernation,
cardiomyopathy, inflammatory or infiltrative diseases. Echocar-
diography provides an assessment of many nonischemic causes
of acute chest pain such as peri-myocarditis, valvular heart
disease, cardiomyopathy, pulmonary embolism or aortic dissec-
tion. It is the imaging technique of choice for detecting compli-
cations of acute MI, includingmyocardial free wall rupture, acute
ventricular septal defect and mitral regurgitation secondary to
papillary muscle rupture or ischaemia.
Radionuclide imaging can be used to assess the amount of
myocardium that is salvaged by acute revascularization.
Tracer is injected at the time of presentation, with imaging
deferred until after revascularization, providing a measure of
myocardium at risk. Before discharge, a second resting injec-
tion provides a measure of final infarct size, and the differ-
ence between the two corresponds to the myocardium that
has been salvaged.
5.6. Applying imaging in late presentation of myocardial
infarction
In case of late presentation after suspected MI, the presence
of regional wall motion abnormality, thinning or scar in the
absence of non-ischaemic causes, provides evidence of past
MI. The high resolution and specificity of late gadolinium
enhancement MRI for the detection of myocardial fibrosis hasmade this a valuable technique with the ability to distinguish
between subendocardial and other patterns of fibrosis with
differentiation between ischaemic heart disease and other
myocardial abnormalities.
The detection of residual or remote ischaemia and/or
ventricular dysfunction provides powerful indicators of later
outcome.6. Incident and recurrent myocardial
infarction, reinfarction
‘‘Incident MI’’ is defined as the individual’s first MI.
‘‘Recurrent MI’’ is an infarction 28 days or more following
an incident MI.
The term ‘‘reinfarction’’ is used for an acute MI that occurs
within 28 days of an incident or recurrent MI. The ECG
diagnosis of suspected reinfarction may be confounded by the
initial evolutionary ECG changes. Reinfarction should be con-
sidered when ST elevation Z0.1 mV recurs, or new pathogno-
monic Q waves appear, in at least two contiguous leads,
particularly when associated with ischaemic symptoms for
20min or longer. Re-elevation of the ST-segment can, however,
also be seen in threatened myocardial rupture and should lead
to additional diagnostic workup. ST depression or LBBB alone
are non-specific findings and should not be used to diagnose
reinfarction. In patients in whom reinfarction is suspected from
clinical signs or symptoms, an immediate measurement of cTn
is recommended. A second sample should be obtained 3–6 h
later. If the cTn concentration is elevated at the 1st examination
of suspected reinfarction, the diagnosis requires a 20% or
greater increase of the cTn value in the second sample. If the
initial cTn concentration is normal, the criteria for new acute
MI apply.
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